Natera, Inc. (NTRA)
USD 132.23
(-4.36%)
USD 132.23
(-4.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -434.8 Million USD | 20.63% |
| 2022 | -547.79 Million USD | -16.13% |
| 2021 | -471.71 Million USD | -105.32% |
| 2020 | -229.74 Million USD | -84.05% |
| 2019 | -124.82 Million USD | 2.6% |
| 2018 | -128.15 Million USD | 5.99% |
| 2017 | -136.31 Million USD | -42.34% |
| 2016 | -95.76 Million USD | -36.27% |
| 2015 | -70.27 Million USD | -1264.03% |
| 2014 | -5.15 Million USD | 86.12% |
| 2013 | -37.11 Million USD | 51.28% |
| 2012 | -76.17 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -67.59 Million USD | 13.37% |
| 2024 Q2 | -37.46 Million USD | 44.58% |
| 2023 Q2 | -110.8 Million USD | 19.08% |
| 2023 Q1 | -136.93 Million USD | 3.95% |
| 2023 FY | -434.8 Million USD | 20.63% |
| 2023 Q4 | -78.03 Million USD | 28.43% |
| 2023 Q3 | -109.03 Million USD | 1.6% |
| 2022 Q2 | -145.15 Million USD | -4.73% |
| 2022 Q3 | -121.48 Million USD | 16.31% |
| 2022 Q4 | -142.57 Million USD | -17.36% |
| 2022 FY | -547.79 Million USD | -16.13% |
| 2022 Q1 | -138.59 Million USD | 1.4% |
| 2021 Q2 | -116.02 Million USD | -81.71% |
| 2021 Q4 | -140.56 Million USD | 7.08% |
| 2021 FY | -471.71 Million USD | -105.32% |
| 2021 Q3 | -151.27 Million USD | -30.38% |
| 2021 Q1 | -63.85 Million USD | 16.44% |
| 2020 Q3 | -58.32 Million USD | 2.2% |
| 2020 Q4 | -76.41 Million USD | -31.02% |
| 2020 FY | -229.74 Million USD | -84.05% |
| 2020 Q1 | -35.37 Million USD | -0.54% |
| 2020 Q2 | -59.63 Million USD | -68.6% |
| 2019 Q3 | -23.13 Million USD | 28.62% |
| 2019 FY | -124.82 Million USD | 2.6% |
| 2019 Q4 | -35.18 Million USD | -52.06% |
| 2019 Q1 | -34.09 Million USD | -7.07% |
| 2019 Q2 | -32.41 Million USD | 4.91% |
| 2018 Q1 | -32.87 Million USD | 27.75% |
| 2018 Q3 | -29.61 Million USD | 12.44% |
| 2018 Q4 | -31.84 Million USD | -7.51% |
| 2018 FY | -128.15 Million USD | 5.99% |
| 2018 Q2 | -33.82 Million USD | -2.89% |
| 2017 Q1 | -35.96 Million USD | 5.13% |
| 2017 Q4 | -45.5 Million USD | -67.79% |
| 2017 FY | -136.31 Million USD | -42.34% |
| 2017 Q3 | -27.11 Million USD | 2.21% |
| 2017 Q2 | -27.73 Million USD | 22.88% |
| 2016 Q1 | -8.68 Million USD | 62.17% |
| 2016 FY | -95.76 Million USD | -36.27% |
| 2016 Q4 | -37.9 Million USD | -45.7% |
| 2016 Q3 | -26.01 Million USD | -12.36% |
| 2016 Q2 | -23.15 Million USD | -166.62% |
| 2015 Q1 | -10 Million USD | -897.77% |
| 2015 Q3 | -17.63 Million USD | 10.42% |
| 2015 FY | -70.27 Million USD | -1264.03% |
| 2015 Q4 | -22.96 Million USD | -30.23% |
| 2015 Q2 | -19.68 Million USD | -96.73% |
| 2014 Q2 | -514 Thousand USD | 94.65% |
| 2014 Q3 | 3.72 Million USD | 824.51% |
| 2014 Q4 | 1.25 Million USD | -66.33% |
| 2014 FY | -5.15 Million USD | 86.12% |
| 2014 Q1 | -9.61 Million USD | -101.76% |
| 2013 Q4 | -4.76 Million USD | 14.1% |
| 2013 Q1 | -17.8 Million USD | 0.0% |
| 2013 FY | -37.11 Million USD | 51.28% |
| 2013 Q3 | -5.54 Million USD | 0.0% |
| 2012 FY | -76.17 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -391.406% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -4271.151% |
| Aspira Women's Health Inc. | -16.69 Million USD | -2505.159% |
| Biodesix, Inc. | -52.14 Million USD | -733.815% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -16438.375% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -5378.145% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -5378.145% |
| Bionano Genomics, Inc. | -232.49 Million USD | -87.017% |
| CareDx, Inc | -190.28 Million USD | -128.501% |
| Check-Cap Ltd. | -17.56 Million USD | -2374.96% |
| Castle Biosciences, Inc. | -57.46 Million USD | -656.623% |
| DarioHealth Corp. | -59.42 Million USD | -631.656% |
| Exact Sciences Corporation | -204.14 Million USD | -112.982% |
| Fulgent Genetics, Inc. | -167.82 Million USD | -159.08% |
| Guardant Health, Inc. | -479.44 Million USD | 9.312% |
| ICON Public Limited Company | 612.33 Million USD | 171.007% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 151.453% |
| Illumina, Inc. | -1.16 Billion USD | 62.549% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -4180.903% |
| iSpecimen Inc. | -11.09 Million USD | -3817.307% |
| Standard BioTools Inc. | -74.65 Million USD | -482.406% |
| MDxHealth SA | -43.1 Million USD | -908.819% |
| 23andMe Holding Co. | -666.7 Million USD | 34.784% |
| Medpace Holdings, Inc. | 282.81 Million USD | 253.743% |
| Myriad Genetics, Inc. | -112 Million USD | -288.215% |
| Mainz Biomed B.V. | -26.29 Million USD | -1553.504% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -4221.97% |
| NeoGenomics, Inc. | -87.96 Million USD | -394.272% |
| Neogen Corporation | -9.42 Million USD | -4515.232% |
| Inotiv, Inc. | -105.14 Million USD | -313.545% |
| OpGen, Inc. | -32.66 Million USD | -1230.948% |
| OPKO Health, Inc. | -188.86 Million USD | -130.22% |
| Psychemedics Corporation | -4.15 Million USD | -10367.044% |
| Prenetics Global Limited | -62.72 Million USD | -593.199% |
| Prenetics Global Limited | -62.72 Million USD | -593.199% |
| Precipio, Inc. | -5.85 Million USD | -7328.686% |
| Personalis, Inc. | -108.29 Million USD | -301.493% |
| RadNet, Inc. | 3.04 Million USD | 14383.87% |
| Sera Prognostics, Inc. | -36.24 Million USD | -1099.716% |
| Sotera Health Company | 51.37 Million USD | 946.312% |
| Neuronetics, Inc. | -30.18 Million USD | -1340.263% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -27987.92% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -27987.92% |
| Trinity Biotech plc | -24.01 Million USD | -1710.313% |
| T2 Biosystems, Inc. | -50.07 Million USD | -768.265% |
| Twist Bioscience Corporation | -208.72 Million USD | -108.312% |
| Exagen Inc. | -23.68 Million USD | -1735.455% |